

DAFTAR PUSTAKA

- Amann, R., Fuchs, B. M. (2008). Single-cell identification in microbial communities by improved fluorescence in situ hybridization techniques. *Nature Reviews Microbiology*. <https://doi.org/10.1038/nrmicro1888>
- Anand, N., Husain, N., Varshney, R., Malhotra, K. P., & Kaif, M. (2021). Molecular classification and stratification of adult diffuse gliomas: A tertiary care center study. *Journal of Carcinogenesis*, 20. DOI: 10.4103/jcar.jcar_17_21. <http://carcinogenesis.com/textasp2021/20/1/20/328121>
- Andrews, C., & Prayson, R. A. (2020). IDH mutations in older patients with diffuse astrocytic gliomas. *Annals of Diagnostic Pathology*, 49, 151653. <https://doi.org/10.1016/j.anndiagpath.2020.151653>
- Azad, A., Jackson, S., Cullinane, C., Natoli, A., Neilsen, P. M., Callen, D. F., ... & Solomon, B. (2011). Inhibition of DNA-Dependent Protein Kinase Induces Accelerated Senescence in Irradiated Human Cancer CellsDNA-PK Blockade and Radiation-Induced Senescence. *Molecular Cancer Research*, 9(12), 1696-1707. <https://doi:10.1158/1541-7786.MCR-11-0312>
- Babikir, H., Wang, L., Shamardani, K., Catalan, F., Sudhir, S., Aghi, M. K., ... & Diaz, A. A. (2021). ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma. *Genome biology*, 22(1), 1-22. doi: 10.1186/s13059-021-02535-4. <https://doi.org/10.1186/s13059-021-02535-4>
- Bai, J., Varghese, J., & Jain, R. (2020). Adult glioma WHO classification update, genomics, and imaging: What the radiologists need to know. *Topics in Magnetic Resonance Imaging*, 29(2), 71-82. doi: 10.1097/RMR.0000000000000234. https://journals.lww.com/topicsinmri/fulltext/2020/04000/adult_glioma_who_classification_update_genomics.2.aspx
- Brat DJ, Aldape K, Colman H, Figarella-Branger D, Fuller GN, Giannini C, Holland EC, Jenkins RB, Kleinschmidt-DeMasters B, Komori T, Kros JM, Louis DN, McLean C, Perry A, Reifenberger G, Sarkar C, Stupp R, van den Bent MJ, von Deimling A, Weller M. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. *Acta Neuropathol*. 2020 Mar;139(3):603-608. doi: 10.1007/s00401-020-02127-9. Epub 2020 Jan 29. PMID: 31996992; PMCID: PMC8443062. <https://pubmed.ncbi.nlm.nih.gov/31996992/>
- Brennan CW, Verhaak RG, McKenna A, Campos B, Nounshmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhi R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna

R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L; TCGA Research Network. The somatic genomic landscape of glioblastoma. *Cell*. 2013 Oct 10;155(2):462-77. doi: 10.1016/j.cell.2013.09.034. Erratum in: *Cell*. 2014 Apr 24;157(3):753. PMID: 24120142; PMCID: PMC3910500. <https://doi.org/10.1016/j.cell.2013.09.034>

Brown, T. J., Bota, D. A., van Den Bent, M. J., Brown, P. D., Maher, E., Aregawi, D., ... & Glantz, M. (2019). Management of low-grade glioma: a systematic review and meta-analysis. *Neuro-oncology practice*, 6(4), 249-258. <https://doi.org/10.1093/nop/npy034>

Bush, N.A.O., Chang, S.M. & Berger, M.S. Current and future strategies for treatment of glioma. *Neurosurg Rev* 40, 1–14 (2017). <https://doi.org/10.1007/s10143-016-0709-8>

Cai J, Zhang C, Zhang W, Wang G, Yao K, Wang Z, Li G, Qian Z, Li Y, Jiang T, Jiang C. ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors. *Oncoscience*. 2016 Sep 6;3(7-8):258-265. doi: 10.18632/oncoscience.317. PMID: 27713914; PMCID: PMC5043074. <https://pubmed.ncbi.nlm.nih.gov/27713914/>

Chami, R., Marrano, P., Teerapakpinyo, C., Arnoldo, A., Shago, M., Shuangshoti, S., & Thorner, P. S. (2019). Immunohistochemistry for ATRX Can Miss ATRX Mutations. *The American Journal of Surgical Pathology*, 43(9), 1203-1211. <https://doi.org/10.1097/PAS.0000000000001322>

Chen R, Smith-Cohn M, Cohen AL, Colman H. Glioma Subclassifications and Their Clinical Significance. *Neurotherapeutics*. 2017 Apr;14(2):284-297. doi: 10.1007/s13311-017-0519-x. PMID: 28281173; PMCID: PMC5398991. <https://pubmed.ncbi.nlm.nih.gov/28281173/>

Chernov MF, Muragaki Y, Kesari S, McCutcheon IE (eds): Intracranial Gliomas. Part I - Surgery. *Prog Neurol Surg*. Basel, Karger, 2018, vol 30, pp 1-11. doi: 10.1159/000464374. <https://doi.org/10.1159/000464374>

Clark O, Yen K, Mellinghoff IK. Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer. *Clin Cancer Res*. 2016 Apr 15;22(8):1837-42. doi: 10.1158/1078-0432.CCR-13-1333. Epub 2016 Jan 27. PMID: 26819452; PMCID: PMC4834266. <https://pubmed.ncbi.nlm.nih.gov/26819452/>

- Cohen AL, Holmen SL, Colman H. IDH1 and IDH2 mutations in gliomas. *Curr Neurol Neurosci Rep*. 2013 May;13(5):345. doi: 10.1007/s11910-013-0345-4. PMID: 23532369; PMCID: PMC4109985. <https://pubmed.ncbi.nlm.nih.gov/23532369/>
- Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. *Cancer*. 1997 Apr 1;79(7):1381-93. doi: 10.1002/(sici)1097-0142(19970401)79:7<1381::aid-cncl16>3.0.co;2-w. PMID: 9083161. <https://pubmed.ncbi.nlm.nih.gov/9083161/>
- Cree IA, Lokuheety D, Peteroen LAN, et al.. WHO Classification of Tumors of the Central Nervous System. World Health Organization Classification of Tumours. Lyon: International Agency for Research on Cancer; 2021.
- Dang, L., Jin, S., & Su, S. M. (2010). IDH mutations in glioma and acute myeloid leukemia. *Trends in molecular medicine*, 16(9), 387-397. <https://doi.org/10.1016/j.molmed.2010.07.002>
- Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. *Ann Oncol*. 2016 Apr;27(4):599-608. doi: 10.1093/annonc/mdw013. PMID: 27005468. <https://pubmed.ncbi.nlm.nih.gov/27005468/>
- Davis ME. Epidemiology and Overview of Gliomas. *Semin Oncol Nurs*. 2018 Dec;34(5):420-429. doi: 10.1016/j.soncn.2018.10.001. Epub 2018 Nov 2. PMID: 30392758. <https://pubmed.ncbi.nlm.nih.gov/30392758/>
- Diwanji TP, Engelman A, Snider JW, Mohindra P. Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. *Adolesc Health Med Ther*. 2017 Sep 22;8:99-113. doi: 10.2147/AHMT.S53391. PMID: 28989289; PMCID: PMC5624597. <https://pubmed.ncbi.nlm.nih.gov/28989289/>
- Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O'Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. *N Engl J Med*. 2015 Jun 25;372(26):2499-508. doi: 10.1056/NEJMoa1407279. Epub 2015 Jun 10. PMID: 26061753; PMCID: PMC4489704. <https://pubmed.ncbi.nlm.nih.gov/26061753/>

- Ferris, S. P., Hofmann, J. W., Solomon, D. A., & Perry, A. (2017). Characterization of gliomas: from morphology to molecules. *Virchows Archiv*, 471(2), 257-269. doi 10.1007/s00428-017-2181-4. <https://link.springer.com/article/10.1007/s00428-017-2181-4>
- Globocan. (2020). <https://gco.iarc.fr/today/>
- Grech N, Dalli T, Mizzi S, Meilak L, Calleja N, Zrinzo A. Rising Incidence of Glioblastoma Multiforme in a Well-Defined Population. *Cureus*. 2020 May 19;12(5):e8195. doi: 10.7759/cureus.8195. PMID: 32572354; PMCID: PMC7302718.
- He, J., Mansouri, A., & Das, S. (2018). Alpha thalassemia/mental retardation syndrome X-linked, the alternative lengthening of telomere phenotype, and gliomagenesis: current understandings and future potential. *Frontiers in Oncology*, 7, 322. <https://doi.org/10.3389/fonc.2017.00322>.
- Grillo, F., Bruzzzone, M., Pigozzi, S., Prosapio, S., Migliora, P., Fiocca, R., & Mastracci, L. (2017). Immunohistochemistry on old archival paraffin blocks: is there an expiry date?. *Journal of Clinical Pathology*, 70(11), 988-993. <http://dx.doi.org/10.1136/jclinpath-2017-204387>
- Haase, S., Garcia-Fabiani, M. B., Carney, S., Altshuler, D., Núñez, F. J., Méndez, F. M., ... & Castro, M. G. (2018). Mutant ATRX: uncovering a new therapeutic target for glioma. *Expert opinion on therapeutic targets*, 22(7), 599-613. <https://doi.org/10.1080/14728222.2018.1487953>
- He, J., Mansouri, A., & Das, S. (2018). Alpha thalassemia/mental retardation syndrome X-linked, the alternative lengthening of telomere phenotype, and gliomagenesis: current understandings and future potential. *Frontiers in Oncology*, 7, 322. <https://doi.org/10.3389/fonc.2017.00322>
- Ho, V. K., Reijneveld, J. C., Enting, R. H., Bienfait, H. P., Robe, P., Baumert, B. G., & Visser, O. (2014). Changing incidence and improved survival of gliomas. *European journal of cancer*, 50(13), 2309-2318. <https://doi.org/10.1016/j.ejca.2014.05.019>
- Hofer S, Rushing E, Preusser M, Marosi C. Molecular biology of high-grade gliomas: what should the clinician know? *Chin J Cancer*. 2014 Jan;33(1):4-7. doi: 10.5732/cjc.013.10218. Epub 2013 Dec 11. PMID: 24325789; PMCID: PMC3905084. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905084/>
- Hu, C., Wang, K., Damon, C., Fu, Y., Ma, T., Kratz, L., ... & Li, Y. (2022). ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma. *Neuro-oncology*, 24(6), 888-900. <https://doi.org/10.1093/neuonc/noab292>

Huang, L. E. (2019). Friend or foe—IDH1 mutations in glioma 10 years on. *Carcinogenesis*, 40(11), 1299-1307. <https://doi.org/10.1093/carcin/bgz134>

Ikemura, M., Shibahara, J., Mukasa, A., Takayanagi, S., Aihara, K., Saito, N., ... & Fukayama, M. (2016). Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas. *Histopathology*, 69(2), 260-267. <https://doi.org/10.1111/his.12927>

Jalal, J. A., Rowandizy, A. I. S., & Ismael, A. T. (2020). Immunohistochemical expression of ATRX in gliomas. *Cellular and Molecular Biology*, 66(7), 131-135. <http://dx.doi.org/10.14715/cmb/2020.66.7.20>

Jha P, Shukla S, Vagha S. (2021). Correlation of IDH1-(R132H) and ATRX Expression with the Histopathological Grades of Glial Tumours: A Study Protocol. *Journal of Pharmaceutical Research International*. <https://journaljpri.com/index.php/JPRI/article/view/35420>

Ji, Y. B., Oh, S. J., Kang, S. G., Heo, J., Kim, S. H., Choi, Y., ... & Suh, J. S. (2016). Terahertz reflectometry imaging for low and high grade gliomas. *Scientific reports*, 6(1), 1-9. <https://doi.org/10.1038/srep36040>

Jiang H, Cui Y, Wang J, Lin S. Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system. *Oncotarget*. 2017 Mar 21;8(12):20354-20361. doi: 10.18632/oncotarget.13555. PMID: 27888628; PMCID: PMC5386767. <https://pubmed.ncbi.nlm.nih.gov/27888628/>

Jiao, Y., Shi, C., Edil, B. H., De Wilde, R. F., Klimstra, D. S., Maitra, A., ... & Papadopoulos, N. (2011). DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. *Science*, 331(6021), 1199-1203. <https://www.science.org/doi/abs/10.1126/science.1200609>

Kabat GC, Etgen AM, Rohan TE. Do steroid hormones play a role in the etiology of glioma? *Cancer Epidemiol Biomarkers Prev*. 2010 Oct;19(10):2421-7. doi: 10.1158/1055-9965.EPI-10-0658. Epub 2010 Sep 14. PMID: 20841389. <https://pubmed.ncbi.nlm.nih.gov/20841389/>

Kannan K, Inagaki A, Silber J, Gorovets D, Zhang J, Kasthuber ER, Heguy A, Petrini JH, Chan TA, Huse JT. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. *Oncotarget*. 2012 Oct;3(10):1194-203. doi: 10.18632/oncotarget.689. PMID: 23104868; PMCID: PMC3717947. <https://pubmed.ncbi.nlm.nih.gov/23104868/>

- Karsy M, Guan J, Cohen AL, Jensen RL, Colman H. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. *Curr Neurol Neurosci Rep*. 2017 Feb;17(2):19. doi: 10.1007/s11910-017-0722-5. PMID: 28271343. <https://pubmed.ncbi.nlm.nih.gov/28271343/>
- Kokkat, T. J., Patel, M. S., McGarvey, D., LiVolsi, V. A., & Baloch, Z. W. (2013). Archived formalin-fixed paraffin-embedded (FFPE) blocks: a valuable underexploited resource for extraction of DNA, RNA, and protein. *Biopreservation and biobanking*, 11(2), 101-106. <http://doi.org/10.1089/bio.2012.0052>
- Komori, T. (2022). Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System. *Laboratory Investigation*, 102(2), 126-133.. <https://doi.org/10.1038/s41374-021-00667-6>
- Koschmann, C., Calinescu, A. A., Nunez, F. J., Mackay, A., Fazal-Salom, J., Thomas, D., ... & Castro, M. G. (2016). ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. *Science translational medicine*, 8(328), 328ra28-328ra28. <https://www.science.org/doi/10.1126/scitranslmed.aac8228>
- Larjavaara, S., Mäntylä, R., Salminen, T., Haapasalo, H., Raitanen, J., Jääskeläinen, J., & Auvinen, A. (2007). Incidence of gliomas by anatomic location. *Neuro-oncology*, 9(3), 319-325. <https://doi.org/10.1215/15228517-2007-016>
- Lin, Z., Yang, R., Li, K., Yi, G., Li, Z., Guo, J., ... & Huang, G. (2020). Establishment of age group classification for risk stratification in glioma patients. *BMC neurology*, 20(1), 1-11. <https://doi.org/10.1186/s12883-020-01888-w>
- Liu, E. M., Shi, Z. F., Li, K. K. W., Malta, T. M., Chung, N. Y. F., Chen, H., ... & Ng, H. K. (2022). Molecular landscape of IDH-wild type, p TERT-wild type adult glioblastomas. *Brain Pathology*, 32(6), e13107. <https://doi.org/10.1111/bpa.13107>
- Liu, Y., Lang, F., Chou, F. J., Zaghoul, K. A., & Yang, C. (2020). Isocitrate dehydrogenase mutations in glioma: Genetics, biochemistry, and clinical indications. *Biomedicines*, 8(9), 294. <https://doi.org/10.3390/biomedicines8090294>
- Liu, J., Zhang, X., Yan, X., Sun, M. E. I., Fan, Y., & Huang, Y. (2019). Significance of TERT and ATRX mutations in glioma. *Oncology letters*, 17(1), 95-102. <https://doi.org/10.3892/ol.2018.9634>

- Louis DN, Ohgaki H, Wiestler OD, et al.. (2016). *WHO Classification of Tumors of the Central Nervous System*. (Vol. 4th revised). Lyon: International Agency for Research on Cancer.
- Louis, D. N., Wesseling, P., Aldape, K., Brat, D. J., Capper, D., Cree, I. A., ... & Ellison, D. W. (2020). cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. *Brain Pathol.* <https://onlinelibrary.wiley.com/doi/epdf/10.1111/bpa.12832>
- Lovejoy, C. A., Li, W., Reisenweber, S., Thongthip, S., Bruno, J., De Lange, T., ... & ALT Starr Cancer Consortium. (2012). Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. *PLoS genetics*, 8(7), e1002772. <https://doi.org/10.1371/journal.pgen.1002772>
- Lu, V. M., O'Connor, K. P., Shah, A. H., Eichberg, D. G., Luther, E. M., Komotar, R. J., & Ivan, M. E. (2020). The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature. *Journal of neuro-oncology*, 148(2), 221-229. <https://doi.org/10.1007/s11060-020-03528-2>
- Ludyga, N., Grünwald, B., Azimzadeh, O., Englert, S., Höfler, H., Tapio, S., & Aubele, M. (2012). Nucleic acids from long-term preserved FFPE tissues are suitable for downstream analyses. *Virchows Archiv*, 460(2), 131-140. DOI 10.1007/s00428-011-1184-9. <https://link.springer.com/article/10.1007/s00428-011-1184-9>
- Manjunath, N., Jha, P., Singh, J., Raheja, A., Kaur, K., Suri, A., ... & Suri, V. (2021). Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance?. *Neurological Sciences*, 42(3), 925-934. <https://doi.org/10.1007/s10072-020-04489-0>
- Mesfin FB, Al-Dhahir MA.(2022). Gliomas. Treasure Island (FL): *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK441874/>
- Miller, J. J., Shih, H. A., Andronesi, O. C., & Cahill, D. P. (2017). Isocitrate dehydrogenase-mutant glioma: evolving clinical and therapeutic implications. *Cancer*, 123(23), 4535-4546. <https://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.31039>
- Molinaro, A. M., Taylor, J. W., Wiencke, J. K., & Wrensch, M. R. (2019). Genetic and molecular epidemiology of adult diffuse glioma. *Nature Reviews*

Neurology, 15(7), 405-417. <https://www.nature.com/articles/s41582-019-0220-2>

Nandakumar, P., Mansouri, A., & Das, S. (2017). The role of ATRX in glioma biology. *Frontiers in oncology*, 7, 236. <https://doi.org/10.3389/fonc.2017.00236>

Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010). Genomic instability—an evolving hallmark of cancer. *Nature reviews Molecular cell biology*, 11(3), 220-228. <https://pubmed.ncbi.nlm.nih.gov/31227792/>

Obara, T., Blonski, M., Brzenczek, C., Mézières, S., Gaudeau, Y., Pouget, C., ... & Taillandier, L. (2020). Adult diffuse low-grade gliomas: 35-year experience at the Nancy France neurooncology unit. *Frontiers in Oncology*, 10, 574679. <https://doi.org/10.3389/fonc.2020.574679>

Ostrom, Q. T., Gittleman, H., Stetson, L., Virk, S., & Barnholtz-Sloan, J. S. (2018). Epidemiology of intracranial gliomas. *Intracranial Gliomas Part I-Surgery*, 30, 1-11. <https://doi.org/10.1159/000464374>

Panduan Penatalaksanaan Tumor Otak. 2016. (pp. 8-9). Jakarta: Kementerian Kesehatan Indonesia. <https://braintumorindonesia.com/wp-content/uploads/2019/09/PNPK-Tumor-Otak-final-20-MAY-2019.pdf>

Papageorgiou, G. I., & Razis, E. D. (2020). CNS tumors in adolescents and young adults: the need for a holistic specialized approach. *JCO Oncology Practice*, 16(4), 155-162. https://ascopubs.org/doi/10.1200/JOP.18.00767?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Peeters, M.C.M., Dirven, L., Koekkoek, J.A.F. et al. (2020). Prediagnostic symptoms and signs of adult glioma: the patients' view. *J Neurooncol* 146, 293–301. <https://doi.org/10.1007/s11060-019-03373-y>.

Perez, A., Huse, J.T. The Evolving Classification of Diffuse Gliomas: World Health Organization Updates for 2021.(2021). *Curr Neurol Neurosci Rep* 21, 67. <https://doi.org/10.1007/s11910-021-01153-8>

Purkait, S., Miller, C. A., Kumar, A., Sharma, V., Pathak, P., Jha, P., & Sarkar, C. (2017). ATRX in diffuse gliomas with its mosaic/heterogeneous expression in a subset. *Brain Pathology*, 27(2), 138-145. <https://onlinelibrary.wiley.com/doi/epdf/10.1111/bpa.12364>

Reuss, D. E., Sahm, F., Schrimpf, D., Wiestler, B., Capper, D., Koelsche, C., & von Deimling, A. (2015). ATRX and IDH1-R132H immunohistochemistry with

subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. *Acta neuropathologica*, 129(1), 133-146. <https://doi.org/10.5167/uzh-104736>

Reynoso-Noverón, N., Mohar-Betancourt, A., Ortiz-Rafael, J. (2021). Epidemiology of Brain Tumors. In: Monroy-Sosa, A., Chakravarthi, S.S., de la Garza-Salazar, J.G., Meneses Garcia, A., Kassam, A.B. (eds) *Principles of Neuro-Oncology*. Springer, Cham. https://doi.org/10.1007/978-3-030-54879-7_2

Sarma, S., Khonglah, Y., Mishra, J., Kakati, A., & Phukan, P. (2021). Gliomas-An experience based on molecular markers. *Journal of Family Medicine and Primary Care*, 10(3), 1341. <https://pubmed.ncbi.nlm.nih.gov/34041176/>

Singh, S., Deora, H., Neyaz, A., Das, K. K., Mehrotra, A., Srivastava, A. K., ... & Jaiswal, S. (2021). Trends in clinico-epidemiology profile of surgically operated glioma patients in a tertiary care center over 12 years—through the looking glass!. *Egyptian Journal of Neurosurgery*, 36(1), 1-8. <https://doi.org/10.1186/s41984-021-00118-w>

Stupp, R., Hegi, M. E., Gilbert, M. R., & Chakravarti, A. (2007). Chemoradiotherapy in malignant glioma: standard of care and future directions. *Journal of Clinical Oncology*, 25(26), 4127-4136.

Takano, S., Ishikawa, E., Sakamoto, N., Matsuda, M., Akutsu, H., Noguchi, M., ... & Matsumura, A. (2016). Immunohistochemistry on IDH 1/2, ATRX, p53 in grade III adult diffuse gliomas. *Brain tumor pathology*, 33(2), 107-116. <https://doi.org/10.1007/s10014-016-0260-x>

Tamimi, A. F., & Juweid, M. (2017). Epidemiology and outcome of glioblastoma. *Exon Publications*, 143-153. <https://doi.org/10.15586/codon.glioblastoma.2017.ch8>.

Topyalin, N., Budak, M., Ozbay, N., Yildiz, M., Kaner, T., Aydin, A., & Gezen, A. F. (2019). A comparative histopathological and immunohistochemical study of Survivin and Ki-67 proteins in glial tumours. *Biotechnology & Biotechnological Equipment*, 33(1), 504-509. <https://doi.org/10.1080/13102818.2019.1591931>

Turcotte-Cardin, V., Young, K. G., & Picketts, D. J. (2019). ATRX tames repetitive DNA within heterochromatin to promote normal brain development and regulate oncogenesis. In *Chromatin Signaling and Neurological Disorders* (pp. 235-257). Academic Press. <https://doi.org/10.1016/B978-0-12-813796-3.00011-0>

- Weller, M., Wick, W., Aldape, K., Brada, M., Berger, M., Pfister, S. M., ... & Reifenberger, G. (2015). Glioma. *Nature reviews Disease primers*, 1(1), 1-18. <https://doi.org/10.1038/nrdp.2015.17>
- Weller, M., Van Den Bent, M., Tonn, J. C., Stupp, R., Preusser, M., Cohen-Jonathan-Moyal, E., ... & Wick, W. (2017). European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. *The lancet oncology*, 18(6), e315-e329. [https://doi.org/10.1016/S1470-2045\(17\)30194-8](https://doi.org/10.1016/S1470-2045(17)30194-8)
- Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., & Bigner, D. D. (2009). IDH1 and IDH2 mutations in gliomas. *New England journal of medicine*, 360(8), 765-773. <https://www.nejm.org/doi/full/10.1056/NEJMoa0808710>
- Xie, Y., Wang, H., Wang, S., Feng, Y., Feng, Y., Fan, S., ... & Hou, T. (2021). Clinicopathological Significance of ATRX Expression in Nasopharyngeal Carcinoma Patients: A Retrospective Study. *Journal of Cancer*, 12(23), 6931. doi: 10.7150/jca.63333. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558651/pdf/jcav12p6931.pdf>